Alan B. Lancz & Associates, Inc. Bristol Myers Squibb CO Transaction History
Alan B. Lancz & Associates, Inc.
- $97.3 Million
- Q4 2024
A detailed history of Alan B. Lancz & Associates, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Alan B. Lancz & Associates, Inc. holds 6,750 shares of BMY stock, worth $363,825. This represents 0.39% of its overall portfolio holdings.
Number of Shares
6,750
Previous 7,350
8.16%
Holding current value
$363,825
Previous $380,000
0.26%
% of portfolio
0.39%
Previous 0.35%
Shares
9 transactions
Others Institutions Holding BMY
# of Institutions
2,729Shares Held
1.57BCall Options Held
30MPut Options Held
31.7M-
Vanguard Group Inc Valley Forge, PA190MShares$10.2 Billion0.19% of portfolio
-
Black Rock Inc. New York, NY159MShares$8.55 Billion0.15% of portfolio
-
Jpmorgan Chase & CO New York, NY96MShares$5.18 Billion0.44% of portfolio
-
State Street Corp Boston, MA95.1MShares$5.13 Billion0.22% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA60.3MShares$3.25 Billion0.65% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $115B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...